MedImmune has entered into a licensing agreement with Omnis Pharmaceuticals.
This agreement will allow MedImmune to combine key agents from its investigational immunotherapy portfolio with Omnis’ lead investigational oncolytic virus programme, a genetically engineered strain of vesicular stomatitis virus (VSV).
|Searching for more deal information? Current Partnering offers the following options:
The programme is currently being studied in a Phase I clinical trial as a monotherapy for the treatment of hepatocellular carcinoma and other cancers that have metastasised to the liver.
Oncolytic viruses are designed to target tumour cells with the killing potency of viruses.
VSV is among a group of naturally occurring viruses that can be engineered to selectively infect tumour cells and destroy them without harming healthy cells.
These oncolytic viruses represent a potentially powerful new tool in the fight against cancer and may be synergistic with various immunotherapies currently being developed by MedImmune.
MedImmune has the license to develop and, if successful, to commercialise Omnis’s lead oncolytic virus programme.
Clinical development of the virus will be accelerated with the objective of rapidly progressing to combination studies with MedImmune’s immunotherapy molecules.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2014
View: Top biotech companies
Report: Top 50 Big Biotech Partnering and M&A Deal Trends